BGIM
BIO icon

Boussard & Gavaudan Investment Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Boussard & Gavaudan Investment Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-648
Closed -$202K – 16
2018
Q3 		$202K Buy
+648
New +$201K 0.01% 15

Other funds holding BIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Boussard & Gavaudan Investment Management's BIO Position: Q4 2018 in Review

Boussard & Gavaudan Investment Management sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2018, closing a stake of 648 shares — an estimated $202K sold.

Boussard & Gavaudan Investment Management first reported a position in BIO in Q3 2018 and held it in 1 quarter. The position peaked at $202K in Q3 2018. 329 funds tracked by Wall St. Rank hold BIO as of Q4 2018.

  • Boussard & Gavaudan Investment Management reported no remaining Bio-Rad Laboratories Class A position as of Q4 2018 after selling out during the quarter.
  • Boussard & Gavaudan Investment Management sold 648 Bio-Rad Laboratories Class A shares in Q4 2018, an estimated $202K.
  • Boussard & Gavaudan Investment Management first reported a position in Bio-Rad Laboratories Class A in Q3 2018 and held it in 1 quarter.
  • Boussard & Gavaudan Investment Management's Bio-Rad Laboratories Class A position peaked at $202K in Q3 2018.
  • 329 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2018.

Based on Boussard & Gavaudan Investment Management's 13F filing for Q4 2018, filed 15 Jan 2019.